The estimated Net Worth of Theodore T Wang is at least $58.8 Tisíc dollars as of 5 June 2020. Theodore Wang owns over 7,586 units of Bellerophon Therapeutics Inc stock worth over $2,437 and over the last 8 years he sold BLPH stock worth over $0. In addition, he makes $56,324 as Independent Director at Bellerophon Therapeutics Inc.
Sign up
Theodore Wang BLPH stock SEC Form 4 insiders trading
Theodore has made over 6 trades of the Bellerophon Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 7,586 units of BLPH stock worth $96,873 on 5 June 2020.
The largest trade he's ever made was buying 450,000 units of Bellerophon Therapeutics Inc stock on 25 January 2019 worth over $315,000. On average, Theodore trades about 25,513 units every 22 days since 2017. As of 5 June 2020 he still owns at least 60,913 units of Bellerophon Therapeutics Inc stock.
You can see the complete history of Theodore Wang stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Theodore Wang biography
Dr. Theodore T. Wang Ph.D. serves as Independent Director of the Company. Dr. Wang has served as the Chief Investment Officer of Puissance Capital Management LP, of which he was a founder, since January 2015. Prior to that, Dr. Wang was a Partner of Goldman, Sachs & Co. (“Goldman”), which he joined in 1996 and with which he served in many leadership positions, mostly recently as Co-Head of U.S. Equities Trading and Global Co-Head of One Delta Trading and a member of the Goldman Sachs Risk Committee. Prior to joining Goldman, Dr. Wang co-founded Xeotron Corp., a company specializing in DNA biochips in Texas. Dr. Wang serves on the board of Ekso Bionics Holdings, Inc., Viewray, Inc. and Tracon Pharmaceuticals, Inc. Dr. Wang holds a Ph.D. in Physics from the University of Minnesota, an M.B.A. from the University of Texas, Austin, and a B.S. from Fudan University, China. Wang is qualified to serve on our Board because of his financial expertise and years of experience.
What is the salary of Theodore Wang?
As the Independent Director of Bellerophon Therapeutics Inc, the total compensation of Theodore Wang at Bellerophon Therapeutics Inc is $56,324. There are 10 executives at Bellerophon Therapeutics Inc getting paid more, with Fabian Tenenbaum having the highest compensation of $1,400,000.
How old is Theodore Wang?
Theodore Wang is 53, he's been the Independent Director of Bellerophon Therapeutics Inc since 2017. There are 7 older and 10 younger executives at Bellerophon Therapeutics Inc. The oldest executive at Bellerophon Therapeutics Inc is Peter Fernandes M. Pharm, 66, who is the Interim Principal Exec. Officer, Chief Regulatory & Safety Officer.
What's Theodore Wang's mailing address?
Theodore's mailing address filed with the SEC is 20 INDEPENDENCE BLVD., SUITE 402, WARREN, NJ, 07059.
Insiders trading at Bellerophon Therapeutics Inc
Over the last 10 years, insiders at Bellerophon Therapeutics Inc have traded over $8,853,497 worth of Bellerophon Therapeutics Inc stock and bought 9,412,012 units worth $57,370,250 . The most active insiders traders include Robert Nelsen, Adam Weinstein a Associates Iv L P Venrock H.... On average, Bellerophon Therapeutics Inc executives and independent directors trade stock every 61 days with the average trade being worth of $10,679. The most recent stock trade was executed by Capital Management Lp Puiss... on 13 October 2023, trading 1,076,841 units of BLPH stock currently worth $107,684.
What does Bellerophon Therapeutics Inc do?
bellerophon therapeutics is a clinical-stage biotherapeutics company focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac diseases. our mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need.
What does Bellerophon Therapeutics Inc's logo look like?
Complete history of Theodore Wang stock trades at Bellerophon Therapeutics Inc, Ekso Bionics Inc, TRACON Pharmaceuticals Inc a ViewRay
Bellerophon Therapeutics Inc executives and stock owners
Bellerophon Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Fabian Tenenbaum,
Chief Executive Officer, Chief Financial Officer, Chief Business Officer, Director -
Peter Fernandes,
Chief Regulatory and Safety Officer -
Assaf Korner,
Chief Financial Officer, Secretary -
Peter Fernandes M. Pharm,
Interim Principal Exec. Officer, Chief Regulatory & Safety Officer -
Martin Dekker,
Vice President - Engineering and Manufacturing -
Jonathan Peacock,
Chairman of the Board -
Crispin Teufel,
Independent Director -
Mary Cloyd,
Independent Director -
Naseem Amin,
Independent Director -
Andre Moura,
Independent Director -
Theodore Wang,
Independent Director -
Scott Bruder,
Independent Director -
Matthew Bennett,
Independent Director -
Wassim Fares,
Chief Medical Officer. -
Amy Edmonds,
Vice President - Clinical Operations and Administration -
Parag Shah,
Vice President - Business Operations -
Dr. Edwin L. Parsley,
Acting Chief Medical Officer -
Dr. Parag Suresh Shah,
VP of Bus. Operations -
Nicholas Laccona,
Principal Financial & Accounting Officer and Sec. -
Cross Border Opportunities ...,
-
Megan Schoeps,
Principal Financial Officer -
Matthew S. Holt,
Director -
Deborah Quinn,
Chief Medical Officer -
Adam Weinstein,
Director -
Daniel Tasse,
Director -
Mountain Investments Ii, Ll...,
-
Life Science Opportunities ...,
-
Associates Iv L P Venrock M...,
-
Associates Iv L P Venrock H...,
-
Associates Iv L P Venrock P...,
-
Associates Iv L P Shah Nimi...,
-
Associates Iv L P Venrock P...,
-
Associates Iv L P Venrock H...,
-
Jens Luehring,
Director -
Venture Fund Vi Lparch Vent...,
-
Martin Meglasson,
Chief Scientific Officer -
Mountain Investments Ii, Ll...,
-
Manesh Naidu,
Chief Business Officer -
Robert Nelsen,
Director -
North America, Inc. Linde,
10% owner -
Amit Agrawal,
Chief Operating Officer -
David Abrams,
Treasurer -
R Scott Huennekens,
Director -
Reinilde Heyrman,
Chief Clinical Dev. Officer -
Associates Iv L Pvenrock En...,
-
Life Science Opportunities ...,
-
Nicholas Laccona,
FINANCIAL OFFICER, (PFO & PAO) -
Capital Management Lp Puiss...,
-
Life Science Opportunities ...,
-
Bobae Kim,
VP Reg. Affairs & Quality